Current
40.1×
5-Year Average
63.2×
All-Time High
243.9×
All-Time Low
7.7×
P/E Ratio daily chart for Eli Lilly (LLY)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/E Ratio for Eli Lilly (LLY) from 2001 to 2025
| 2025 | $965.06B | $20.64B | 46.8× | -18.7× | |
| 2024 | $692.90B | $10.59B | 65.4× | -34.6× | |
| 2023 | $524.27B | $5.24B | 100.0× | +44.4× | |
| 2022 | $347.61B | $6.24B | 55.7× | +8.5× | |
| 2021 | $263.42B | $5.58B | 47.2× | +21.1× | |
| 2020 | $161.51B | $6.19B | 26.1× | +10.9× | |
| 2019 | $125.85B | $8.32B | 15.1× | -21.7× | |
| 2018 | $118.93B | $3.23B | 36.8× | — | |
| 2017 | $88.85B | −$204.10M | — | — | |
| 2016 | $80.97B | $2.74B | 29.6× | -9.1× | |
| 2015 | $93.13B | $2.41B | 38.7× | +6.6× | |
| 2014 | $76.62B | $2.39B | 32.1× | +19.9× | |
| 2013 | $56.96B | $4.68B | 12.2× | -1.7× | |
| 2012 | $56.55B | $4.09B | 13.8× | +3.2× | |
| 2011 | $46.37B | $4.35B | 10.7× | +3.0× | |
| 2010 | $38.86B | $5.07B | 7.7× | -1.4× | |
| 2009 | $39.21B | $4.33B | 9.1× | — | |
| 2008 | $44.08B | −$2.07B | — | — | |
| 2007 | $58.20B | $2.95B | 19.7× | -1.5× | |
| 2006 | $56.51B | $2.66B | 21.2× | -9.8× | |
| 2005 | $61.45B | $1.98B | 31.0× | -2.9× | |
| 2004 | $61.37B | $1.81B | 33.9× | +4.3× | |
| 2003 | $75.89B | $2.56B | 29.6× | +4.4× | |
| 2002 | $68.26B | $2.71B | 25.2× | -5.2× | |
| 2001 | $84.56B | $2.78B | 30.4× | — |
- 202546.8×
- 202465.4×
- 2023100.0×
- 202255.7×
- 202147.2×
- 202026.1×
- 201915.1×
- 201836.8×
- 2017—
- 201629.6×
- 201538.7×
- 201432.1×
- 201312.2×
- 201213.8×
- 201110.7×
- 20107.7×
- 20099.1×
- 2008—
- 200719.7×
- 200621.2×
- 200531.0×
- 200433.9×
- 200329.6×
- 200225.2×
- 200130.4×
About P/E Ratio at Eli Lilly (LLY)
Eli Lilly (LLY) P/E ratio is 40.1× as of June 5, 2026. The 5-year average is 63.2×. The sector median currently stands at 25.0×. The current ratio is at the 14th percentile of its own 10-year history.
Eli Lilly (LLY) historical P/E ratio has ranged from a low of 7.7× (2010) to a high of 243.9× (2018) in the available daily series.
The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.
Eli Lilly P/E Ratio by Year
Eli Lilly P/E Ratio 2025: 46.8×
Eli Lilly (LLY) P/E ratio in 2025 was 46.8×, contracted from 65.4× the prior year.
Eli Lilly P/E Ratio 2024: 65.4×
Eli Lilly (LLY) P/E ratio in 2024 was 65.4×, contracted from 100.0× the prior year.
Eli Lilly P/E Ratio 2023: 100.0×
Eli Lilly (LLY) P/E ratio in 2023 was 100.0×, expanded from 55.7× the prior year.
Eli Lilly P/E Ratio 2022: 55.7×
Eli Lilly (LLY) P/E ratio in 2022 was 55.7×, expanded from 47.2× the prior year.
Eli Lilly P/E Ratio 2021: 47.2×
Eli Lilly (LLY) P/E ratio in 2021 was 47.2×.
Sector peers by P/E Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/E Ratio — table
Healthcare peers of Eli Lilly (LLY), ranked by P/E ratio.
| 22.2× | |
| 22.2× | |
| 21.7× | |
| 21.6× | |
| 21.6× | |
| 21.1× | |
| 21.1× | |
| 21.0× | |
| 20.9× | |
| 20.7× | |
| 20.4× | |
| 19.7× | |
| 18.9× | |
| 18.8× | |
| 18.5× | |
| 18.2× | |
| 17.0× | |
| 15.8× | |
| 13.3× | |
| 13.1× | |
| 12.3× | |
| 11.1× | |
| 8.6× | |
| 7.9× | |
| 7.2× |
- 22.2×
- 22.2×
- 21.7×
- 21.6×
- 21.6×
- 21.1×
- 21.0×
- 20.9×
- 20.7×
- 19.7×
- 18.9×
- 18.5×
- 15.8×
- 13.3×
- 13.1×
- 11.1×
- 7.9×
Frequently asked questions
Eli Lilly (LLY) Key Financials
Charts, filings, and peer comparison for every metric